Nicotinic acetylcholine receptor alpha subunit (nAChR α subunit)

The **nicotinic acetylcholine receptor alpha subunit** refers to one of several homologous proteins that form part of pentameric ligand-gated ion channels known as nicotinic acetylcholine receptors. These receptors are found throughout the nervous system and at neuromuscular junctions. Each functional nAChR consists of five transmembrane subunits arranged symmetrically around a central pore; two or more are typically designated as “alpha” because they contain key residues forming part of the agonist binding site[1][2][3]. In mammals, there are ten neuronal types (α2–α10) and one muscle type (α1), each encoded by separate genes. The combination and arrangement determine pharmacological properties, tissue distribution, developmental expression patterns, and physiological roles—ranging from mediating fast synaptic transmission in muscles to modulating neurotransmitter release in neurons. Dysfunction or autoimmunity against certain forms leads to diseases such as myasthenia gravis or contributes to addiction biology through nicotine’s action on brain-expressed forms[1][2][3].

Other names

nAChR alpha subunitAcetylcholine receptor alpha chainCHRNA (gene family prefix)Muscle-type nicotinic acetylcholine receptor alpha 1 (for CHRNA1)Neuronal nicotinic acetylcholine receptor alpha x (where x = 2–10)

Drugs targeting this molecule act via mechanisms such as: - Agonism at the ligand-binding site to activate the ion channel and depolarize the cell membrane. - Antagonism/blockade of the ligand-binding site to prevent activation by endogenous acetylcholine. - Allosteric modulation altering sensitivity or desensitization kinetics.